OrthodontiCell Advances Towards U.S. Phase II Study with New Funding

Securing the Future of Orthodontic Innovation

In a significant development for the field of orthodontics, OrthodontiCell, Inc. has announced the acquisition of sufficient capital to finalize the necessary testing for its planned Phase II pivotal clinical study in the United States. This financial milestone marks a critical step forward in the company's mission to revolutionize orthodontic treatment through the development of bioelectric technology. The technology in question is designed to expedite tooth movement, thereby reducing the duration of orthodontic care and enhancing the overall patient experience. With this funding secured, OrthodontiCell is poised to focus on completing the requisite testing and preparing its regulatory submission, a move that will pave the way for the anticipated U.S. study.

Innovative Bioelectric Technology

OrthodontiCell's cutting-edge approach involves the use of controlled bioelectric stimulation in conjunction with traditional orthodontic methods. The primary aim is to shorten the treatment timeline, offering a more efficient path to achieving a healthy and confident smile. As the company advances its program, the forthcoming Phase II study will serve as a pivotal evaluation of both the safety and efficacy of this innovative technology. The study will specifically assess the potential of bioelectric stimulation to reduce the time required for teeth straightening, an advancement that could transform patient care within the orthodontic field. Details regarding the final study design, participating centers, and enrollment schedule will be disclosed as the program progresses.

A Step Closer to Clinical Milestones

Mark Terrill, CEO of OrthodontiCell, emphasizes the profound impact a shortened orthodontic treatment can have on patients and their families. He notes that the recent capital acquisition is a crucial step towards the company's next clinical milestone, providing the necessary resources to propel the application process forward. It is important to note that the funding obtained covers only the remaining testing required to support the planned application; separate funding will be sought to conduct the pivotal study itself. While the technology remains investigational at this stage, the planned U.S. study's initiation will depend on the completion of testing and the attainment of applicable regulatory and ethics approvals. As OrthodontiCell continues its journey towards transforming orthodontic treatment, the anticipation surrounding the potential benefits of its bioelectric technology remains high. For more information about OrthodontiCell and its innovative advancements, visit OrthodontiCell.